Drug Profile
Monoclonal antibody TNT-3
Alternative Names: TNT-3; tumour necrosis treatment-3Latest Information Update: 30 Apr 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 07 May 1999 A preclinical study has been added to the pharmacodynamics section
- 25 Nov 1998 New profile
- 25 Nov 1998 Preclinical development for Solid tumours in USA (Unknown route)